INNATE PHARMA : Third quarter 2017 report
Third quarter 2017 report Cash, cash equivalents and financial assets[*] amounting to €195.7 million Robust cash position allows for further investment in portfolio of proprietary immuno-oncology programs Innate Pharma continues its clinical development …